Challenges of the differential diagnosis between the subtypes of the junctional epidermolysis bullosa: presentation of two clinical cases

Cover Page


Cite item

Full Text

Abstract

Background: Epidermolysis bullosa (EB) is a rare hereditary skin disease. It is subdivided into EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB) and Kindler syndrome. JEB is diagnosed in 2 per 1,000,000 of the population. There are few descriptions of clinical JEB cases in the literature. Clinical diagnosis of JEB and its subtypes is a challenge, especially in the early age. The paper presents 2 clinical cases of JEB in patients of the West Slavonic origin. Clinical case No. 1 was a girl of Ukrainian ethnicity, with confirmed definitive diagnosis of severe generalized JEB. Molecular genetic tests identified mutations of the LAMA3 gene that had not been described previously. The patient died at the age of 24 months from acute respiratory failure. When the patient was alive, her EB type and subtype was not possible to identify, because she had a combination of clinical manifestations typical for various JEB subtypes. Despite such symptoms as hoarse voice, stenoses, granulation tissue of typical location, laryngeal granulations, the girl was steadily gaining weight, with some periods of relative stabilization of the skin disease; she also had longer life longevity than was common for patients with severe generalized JEB. All this made a precise diagnosis difficult. Clinical case No. 2: an ethnic Russian boy with non-classified JEB. Molecular genetic testing helped to identify a homozygote mutation in the LAMA3 gene that had not been previously described; reliable determination of the subtype was not possible. The patient had mixed clinical manifestation similar both to generalized severe JEB and to laryngo-onycho-cutaneous (LOC) syndrome. During his lifetime, the patient was clinically diagnosed with Hallopeau acrodermatitis and LOC syndrome. The differential diagnostic problems were associated with the presence of signs not typical for each of the subtypes. Significant life longevity of the proband is not characteristic for severe generalized JEB (at the time of the publication the patient is 13 years old), whereas for LOC syndrome the absence of eye involvement is not typical, as well as severe laryngeal involvement at adolescence.

Conclusion: Detailed descriptions of phenotype of JEB subtypes including rare and minimal clinical signs can be useful to study the clinical manifestations and natural course of the disease, including its differential diagnosis.

About the authors

Yu. Yu. Kotalevskaya

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: kotalevskaya@mail.ru

Yuliya Yu. Kotalevskaya – MD, PhD, Geneticist, Head of the Consultative Department, Center for Medical Genetics  

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

N. M. Marycheva

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology

Email: fake@neicon.ru

Nataliya M. Marycheva – MD, Dermatovenerologist  

17 Leninskiy prospekt, Moscow, 119071

Russian Federation

References

  1. Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, McGrath JA, Mellerio JE, Murrell DF, Shimizu H, Uitto J, Vahlquist A, Woodley D, Zambruno G. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol. 2008;58(6):931–50. doi: 10.1016/j.jaad.2008.02.004.
  2. Fine JD, Bruckner-Tuderman L, Eady RA, Bauer EA, Bauer JW, Has C, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, Marinkovich MP, Martinez AE, McGrath JA, Mellerio JE, Moss C, Murrell DF, Shimizu H, Uitto J, Woodley D, Zambruno G. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70(6):1103–26. doi: 10.1016/j.jaad.2014.01.903.
  3. Fine JD, Bauer EA, McGuire J, Moshell A, editors. Epidermolysis bullosa: Clinical, epidemiologic, and laboratory advances and the findings of the National Epidermolysis Bullosa Registry. Baltimore, MD: Johns Hopkins University Press; 1999.
  4. Vahlquist A, Tasanen K. Epidermolysis bullosa care in Scandinavia. Dermatol Clin. 2010;28(2): 425–7, xv. doi: 10.1016/j.det.2010.02.018.
  5. Horn HM, Priestley GC, Eady RA, Tidman MJ. The prevalence of epidermolysis bullosa in Scotland. Br J Dermatol. 1997;136(4):560–4. doi: 10.1046/j.1365-2133.1997.d01-1235.x.
  6. Кубанов АА, Альбанова ВИ, Карамова АЭ, Чикин ВВ, Мелехина ЛЕ, Богданова ЕВ. Распространенность врожденного буллезного эпидермолиза у населения Российской Федерации. Вестник дерматологии и венерологии. 2015;(3):21–30. doi: 10.25208/0042-4609-2015-0-3-21-30.
  7. Pfendner EG, Lucky AW. Junctional epidermolysis bullosa. GeneReviews [Internet]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1125/.
  8. Kelly-Mancuso G, Kopelan B, Azizkhan RG, Lucky AW. Junctional epidermolysis bullosa incidence and survival: 5-year experience of the Dystrophic Epidermolysis Bullosa Research Association of America (DebRA) nurse educator, 2007 to 2011. Pediatr Dermatol. 2014;31(2): 159–62. doi: 10.1111/pde.12157.
  9. Файн Дж.-Д., Хинтнер Х, ред. Буллезный эпидермолиз. Пер. с англ. под ред. Ю.Ю. Коталевской. М.: Практика; 2014. 358 с.
  10. Kowalewski C, Bremer J, Gostynski A, Wertheim-Tysarowska K, Wozniak K, Bal J, Jonkman MF, Pasmooij AM. Amelioration of junctional epidermolysis bullosa due to exon skipping. Br J Dermatol. 2016;174(6):1375–9. doi: 10.1111/bjd.14374.
  11. Barzegar M, Mozafari N, Kariminejad A, Asadikani Z, Ozoemena L, McGrath JA. A new homozygous nonsense mutation in LAMA3A underlying laryngo-onycho-cutaneous syndrome. Br J Dermatol. 2013;169(6):1353–6. doi: 10.1111/bjd.12522.
  12. Salvestrini C, McGrath JA, Ozoemena L, Husain K, Buhamrah E, Sabery N, Leichtner A, Rufo PA, Perez-Atayde A, Orteu CH, Torrente F, Heuschkel RB, Thomson MA, Murch SH. Desquamative enteropathy and pyloric atresia without skin disease caused by a novel intracellular beta4 integrin mutation. J Pediatr Gastroenterol Nutr. 2008;47(5):585–91. doi: 10.1097/MPG.0b013e31817af98d.
  13. Fine JD. Epidemiology of Inherited Epidermolysis Bullosa Based on Incidence and Prevalence Estimates From the National Epidermolysis Bullosa Registry. JAMA Dermatol. 2016;152(11):1231–8. doi: 10.1001/jamadermatol.2016.2473.
  14. Shabbir G, Hassan M, Kazmi A. Laryngo-onycho-cutaneous syndrome – a study of 22 cases. Biomedica. 1986;2:15–25.
  15. ЛОК (ларинго-онихо-кутанный) синдром. ORPHA:2407 [Интернет]. Доступно на: https://www.orpha.net/data/patho/RU/LOC-syndrome-RUrusAbs2233.pdf.
  16. Kadyan A, Aralikatti A, Shah S, Jewell R, Paul L, Darling J, Wood M, Gooi J, Morrell AJ, Newton Bishop JA, Marr JE. Laryngo-onycho-cutaneous syndrome. Ophthalmology. 2010;117(5):1056– 1056.e2. doi: 10.1016/j.ophtha.2009.11.019.
  17. Cohn HI, Murrell DF. Laryngo-onycho-cutaneous syndrome. Dermatol Clin. 2010;28(1): 89–92. doi: 10.1016/j.det.2009.10.010.
  18. Hirsch T, Rothoeft T, Teig N, Bauer JW, Pellegrini G, De Rosa L, Scaglione D, Reichelt J, Klausegger A, Kneisz D, Romano O, Secone Seconetti A, Contin R, Enzo E, Jurman I, Carulli S, Jacobsen F, Luecke T, Lehnhardt M, Fischer M, Kueckelhaus M, Quaglino D, Morgante M, Bicciato S, Bondanza S, De Luca M. Regeneration of the entire human epidermis using transgenic stem cells. Nature. 2017;551(7680): 327–32. doi: 10.1038/nature24487.
  19. Fine JD, Johnson LB, Weiner M, Suchindran C. Cause-specific risks of childhood death in inherited epidermolysis bullosa. J Pediatr. 2008;152(2):276–80. doi: 10.1016/j.jpeds.2007.06.039.
  20. Fine JD, Johnson LB, Weiner M, Stein A, Cash S, Deleoz J, Devries DT, Suchindran C. Eye involvement in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry. Am J Ophthalmol. 2004;138(2):254– 62. doi: 10.1016/j.ajo.2004.03.034.
  21. Pearson RW, Potter B, Strauss F. Epidermolysis bullosa hereditaria letalis. Clinical and histological manifestations and course of the disease. Arch Dermatol. 1974;109(3):349–55. doi: 10.1001/archderm.1974.01630030009001.
  22. Yuen WY, Duipmans JC, Molenbuur B, Herpertz I, Mandema JM, Jonkman MF. Longterm follow-up of patients with Herlitz-type junctional epidermolysis bullosa. Br J Dermatol. 2012;167(2):374–82. doi: 10.1111/j.1365-2133.2012.10997.x.
  23. Vidal F, Baudoin C, Miquel C, Galliano MF, Christiano AM, Uitto J, Ortonne JP, Meneguzzi G. Cloning of the laminin alpha 3 chain gene (LAMA3) and identification of a homozygous deletion in a patient with Herlitz junctional epidermolysis bullosa. Genomics. 1995;30(2):273–80. doi: 10.1006/geno.1995.9877.
  24. Schneider H, Mühle C, Pacho F. Biological function of laminin-5 and pathogenic impact of its deficiency. Eur J Cell Biol. 2007;86(11–12): 701–17. doi: 10.1016/j.ejcb.2006.07.004.
  25. Hammersen J, Has C, Naumann-Bartsch N, Stachel D, Kiritsi D, Söder S, Tardieu M, Metzler M, Bruckner-Tuderman L, Schneider H. Genotype, Clinical Course, and Therapeutic Decision Making in 76 Infants with Severe Generalized Junctional Epidermolysis Bullosa. J Invest Dermatol. 2016;136(11):2150–7. doi: 10.1016/j.jid.2016.06.609.
  26. Pacho F, Zambruno G, Calabresi V, Kiritsi D, Schneider H. Efficiency of translation termination in humans is highly dependent upon nucleotides in the neighbourhood of a (premature) termination codon. J Med Genet. 2011;48(9):640–4. doi: 10.1136/jmg.2011.089615.
  27. Mühle C, Jiang QJ, Charlesworth A, Bruckner-Tuderman L, Meneguzzi G, Schneider H. Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: molecular basis and clinical course of Herlitz disease. Hum Genet. 2005;116(1–2):33–42. doi: 10.1007/s00439-004-1210-y.
  28. Ayoub N, Tomb R, Charlesworth A, Meneguzzi G. Junctional epidermolysis bullosa. Identification of a new mutation in two Lebanese families. Ann Dermatol Venereol. 2005;132(6–7 Pt 1):550–3.
  29. Laryngoonychocutaneous syndrome; LOCS. OMIM # 245660 [Internet]. Available from: http://omim.org/entry/245660#1.
  30. McLean WH, Irvine AD, Hamill KJ, Whittock NV, Coleman-Campbell CM, Mellerio JE, Ashton GS, Dopping-Hepenstal PJ, Eady RA, Jamil T, Phillips R, Shabbir SG, Haroon TS, Khurshid K, Moore JE, Page B, Darling J, Atherton DJ, Van Steensel MA, Munro CS, Smith FJ, McGrath JA. An unusual N-terminal deletion of the laminin alpha3a isoform leads to the chronic granulation tissue disorder laryngo-onycho-cutaneous syndrome. Hum Mol Genet. 2003;12(18):2395–409. doi: 10.1093/hmg/ddg234.
  31. Prodinger C, Klausegger A, Diem A, Bauer JW, Laimer M. Laryngo-onycho-cutaneous (-like) syndrome due to mutated Plectin. J Eur Acad Dermatol Venereol. 2017;31(8):e373–4. doi: 10.1111/jdv.14173.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Kotalevskaya Y.Y., Marycheva N.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies